Abstract The incidence and prevalence of Crohn's disease are increasing, particularly in the Western world and Asia. Corticosteroids have been used for decades to treat active Crohn's disease and remain the mainstay in the management of moderate-to-severe relapses in Crohn's disease. The use of corticosteroids, despite their efficacy, may be associated with several drawbacks. This review article provides a comprehensive account of the role of corticosteroids in inducing remission in adult patients with Crohn's disease, including aspects such as approaches to corticosteroid sparing and to minimize the risk of corticosteroid dependency, as well as the role of newer corticosteroids such as budesonide in reducing systemic adverse effects.
Introduction
Crohn's disease (CD) is a life-long, chronic inflammatory condition characterised by repetitive flares and periods of inactive disease. Its relapsing behaviour frequently necessitates a combination of approaches to effectively treat active disease. In clinical practice, active CD is defined by the presence of symptoms such as chronic or nocturnal diarrhoea, abdominal pain and rectal bleeding [1] ; in clinical trials, disease activity is measured by the Crohn's Disease Activity Index (CDAI) score of C150 [2, 3] . One challenging goal in the therapy of CD flares is to induce remission in active CD. Several agents are available for the induction of remission of CD, such as corticosteroids and anti-tumour necrosis factor (TNF) antibodies [4] . The selection of an optimal treatment depends on several factors, including severity of disease, location, previous response to therapy and co-morbidities.
Historically, prior to the advent of biological therapies, corticosteroids had been the most effective class of medication for the treatment of acute flares of CD in adults [5] and children [6] . Corticosteroids down-regulate the transcription of genes involved in proinflammatory cytokine production such as interleukin (IL)-1, IL-6, NF-jB and TNF and inhibit the expression of adhesion molecules in inflamed tissues and the trafficking of activated immune cells [7] [8] [9] . Corticosteroids have been used for the treatment of inflammatory bowel disease since the 1950s [10] . In a pivotal trial, Truelove and Witts showed that oral cortisone at a dose of 100 mg daily effectively induced remission in patients with active ulcerative colitis [10] . In patients with CD, corticosteroids are used to induce remission in moderate-to-severe ileo-colonic disease, extensive small bowel disease and pure colonic disease [11] . Response to corticosteroids has been defined in several clinical studies as clinical improvement after treatment with high-dose oral corticosteroids (usually 40-60 mg prednisone/day) within 30 days or clinical improvement after treatment with high-dose intravenous corticosteroids within 7-10 days [4, 12, 13] . Conversely, patients who do not respond to corticosteroids within this timeframe have been defined as corticosteroid refractory or corticosteroid resistant [4] . Patients, who initially respond to corticosteroids but then relapse with corticosteroid tapering or shortly after corticosteroid discontinuation and require reinstitution of corticosteroid therapy at doses of 10-30 mg/day to maintain symptom control have been defined as corticosteroid dependent [4, 12] . More than 50 % of patients treated acutely with corticosteroids will become corticosteroid dependent or corticosteroid resistant [13] [14] [15] [16] [17] , particularly smokers, or those with colonic disease [18] .
Corticosteroids are characterised by several adverse effects that limit their use in the short and long term. Adverse effects can be classified as early, due to prolonged use or abrupt withdrawal [11] . Daily use for more than 2-3 weeks significantly increases the risk of adverse events [19] . The most commonly reported adverse effects are acne, arterial hypertension, hirsutism, striae, moon face, ecchymoses, cataracts, glaucoma, suppression of the adrenal function and infection (mainly increased risk of abdominal and pelvic abscess in CD patients) [1, 15, [20] [21] [22] . Additionally, corticosteroids can induce a loss of bone mineral density and increase the risk of fractures [23] [24] [25] . Owing to this significantly increased risk of osteoporosis, whenever corticosteroids are used in inflammatory bowel disease patients, an initial baseline DEXA scan as well as supplementation of calcium and vitamin D are warranted once corticosteroid therapy is initiated [26] [27] [28] . Other adverse effects include hyperlipidaemia, hypokalaemia, hyperglycaemia and hypocalcaemia [29, 30] . In a multivariate analysis by Lichtenstein et al. [31] , the use of prednisone was associated with an increased risk of infection (odds ratio (OR) 2.21, 95 % confidence interval (CI) 1.46-3.34, p \ 0.001) and mortality (OR 2.10, 95 % CI 1.15-3.83; p = 0.016). Therefore, it is important to weigh the risk-benefit ratio before use. In clinical practice, corticosteroid-free remission represents an important primary endpoint in the treatment of CD patients.
This review article focuses on the role of corticosteroids in inducing remission in adult patients with CD. It contains aspects such as approaches to corticosteroid sparing and minimizing the risk of corticosteroid dependency, as well as the role of newer corticosteroids such as budesonide in reducing systemic adverse effects.
A literature search matching terms ''prednisone'', ''prednisolone'', ''6-methylprednisolone'' and ''budesonide'' with the term ''Crohn's disease'' was performed in the PubMed, MEDLINE, Cochrane Central Register of Controlled Trials, and EMBASE databases. All relevant articles published in English and German between September 1960 and September 2013 were reviewed.
Conventional Corticosteroids

Induction of Remission
Conventional corticosteroids, such as prednisone, prednisolone and 6-methylprednisolone, are highly effective at inducing clinical remission in active CD [1, 15, 21] and are perceived as the most effective therapeutic option for inducing remission of mild to moderate CD. They can induce clinical remission in moderate-to-severe ileocaecal, colonic or small bowel CD as well as in oesophageal and gastric localisations in combination with proton pump inhibitors [4] . For an overview of all randomised, doubleblind, placebo-controlled trials see Table 1 . In a study by Summers et al. [21] [15] . After 1 week of methylprednisolone, the dose was gradually tapered to 12 mg/day or placebo. The cycle of corticosteroid treatment was repeated if remission was not achieved by weeks 6 and 12. At week 18, the percentage of patients in clinical remission (CDAI of\150) was 83 and 37.9 %, respectively, for corticosteroid treatment and placebo (NNT = 2).
In a third study, Brignola et al. [32] treated 18 patients with methylprednisolone 0.25 mg/kg/day or placebo. At n.a.
6 months, a relapse rate of 78 % was observed in the placebo group compared with an 11 % relapse rate in the methylprednisolone group. Several studies compared the benefit of corticosteroids over 5-aminosalicylate (5-ASA) medications for the induction of remission. The two early studies by Summers et al. (using sulphasalazine at the equivalent of 2 g/day of 5-ASA) and Malchow et al. (using sulphasalazine at the equivalent of 1.2 g/day of 5-ASA) both had 5-ASA arms in their study protocol [15, 21] . At lower 5-ASA concentrations, corticosteroids revealed a clear benefit over 5-ASA therapy [15, 21, 33, 34] . Studies comparing corticosteroids with higher doses of 5-ASA (3-4.5 g/day) did not show a benefit of corticosteroids, although long-term follow-up was not available [34] [35] [36] [37] .
Corticosteroids are important drugs in inducing clinical remission. They also have a limited capacity to induce mucosal healing or at least endoscopic improvement. Two studies showed a 29 % rate of endoscopic remission with corticosteroid therapy [38, 39] . Similarly, limited efficacy has been shown in patients with complicated CD. The presence of structuring and penetrating disease is likely to respond poorly to corticosteroids [16] . Their use in cases of fistulising disease is also limited because of evidence of an increased need for surgery [40, 41] and death occurring as a result of septic complications [15] .
No appropriate dose-ranging studies have been performed to evaluate corticosteroid dosing or dose schedules for CD. Comparable clinical effects have been reported from placebo-controlled and active-comparator trials with approximately 50-70 % of patients achieving a clinical remission over 8-17 weeks receiving the equivalent of prednisone, 0.5-0.75 mg/kg (or 40 mg/day) daily [21, [42] [43] [44] . Higher doses of prednisone (1 mg/kg/day) or methyl prednisolone (1 mg/kg/day) have demonstrated slightly higher response rates of 80-90 % [15, 38] . Several studies have also studied dexamethasone and betamethasone in CD patients, but this will not be the main focus of this review [45] [46] [47] .
Maintenance of Remission
Conventional corticosteroids are not indicated for maintaining remission of CD because of their lack of efficacy and the potential multitude of systemic adverse effects [2] . One small study reported methylprednisolone to be more beneficial than placebo at maintaining remission [32] . This result could not be reproduced in two larger studies and one smaller study comparing prednisone and 6-methylprednisonolone with placebo [15, 21, 48] . The study by Summers et al. (the National Cooperative Crohn's Disease Study) reported that 0.25 mg/kg/day was not effective at a 2-year follow-up at preventing relapses among patients in remission [21] . The study by Malchow et Cooperative Crohn's Disease Study) determined that 6-methylprednisolone 48 mg/day once daily was not better than placebo at maintaining remission at 2 years [15] . In the study by Smith and colleagues from Cardiff, Wales, prednisone 7.5 mg/day or placebo was given to 64 CD patients with no beneficial effect regarding clinical relapse [48] . In summary, a Cochrane Database Review concluded that conventional corticosteroids were not an effective maintenance therapy for up to 2 years [49] . Therefore, long-term use of corticosteroids should be avoided and the introduction of corticosteroid-sparing agents such as azathioprine or 6-mercaptpurine should be favoured [50] [51] [52] .
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3 Non-Systemic Corticosteroids (Budesonide)
Induction of Remission
More recently, topically active formulations of corticosteroids such as budesonide have been developed to reduce systematic availability and adverse events while maintaining efficacy. Budesonide is a locally acting, topically delivered corticosteroid that undergoes extensive first-pass hepatic metabolism (80-90 %) and, accordingly, has low systemic absorption [53] . Thus, the benefits of corticosteroids in managing mild to moderate CD can be achieved with a reduced risk of systemic adverse effects. Both the ECCO and the AGA recommend budesonide as a first-line therapy for mild to moderate CD of the ileum and proximal colon [4, 26] . For patients with CD, two formulations that target the ileocaecal tract have been developed: pHdependent (Budenofalk Ò or Budeson Ò -Dr. Falk Pharma, Freiburg, Germany) and controlled ileal release (Entocort Ò -Astra Zeneca). The current literature is summarised in Table 2 .
Budesonide vs. placebo
Several studies have been published on the induction of remission of CD with budesonide. The two main studies showing the superiority of budesonide compared with placebo and inducing clinical remission in patients with active luminal disease are those by Greenberg et al. and Tremaine et al. [54, 55] . Both trials included patients with terminal ileal, ileocolonic or right-sided colonic CD. Greenberg et al. reported that budesonide 9 mg/day for 8 weeks was significantly more effective than placebo at induction of remission in active CD (51 vs. 20 %, respectively, p \ 0.001) [54] . Tremaine et al. found that budesonide 9 mg/day for 8 weeks resulted in remission in 48 % of active CD patients but was not significantly different from placebo because of a high remission rate of 33 % in the placebo-treated patients (p \ 0.05) [55] . When those two trials were summarized in a meta-analysis, a clear statistically significant effect in favour of budesonide could be found with a NNT = 5 (budesonide achieving remission in one patient) [56] .
Budesonide vs. corticosteroids
Eight randomised controlled trials have compared the efficacy of budesonide with oral systemic corticosteroids or beclomethasone dipropionate. All trials recruited patients with distal ileal, ileocecal or right-sided colonic CD, but most did not report exact patient numbers according to disease location. The remission rates in these studies were 51-60 % in the budesonide group and 52-89 % in the corticosteroid group [42, 43, [57] [58] [59] [60] [61] [62] . The results of these trials have been summarized in two Cochrane Reviews and show that budesonide is comparable to prednisone in inducing clinical remission in patients with ileo-colonic CD [63, 64] .
Budesonide vs. 5-ASA
Only one study reported on the induction of remission of budesonide vs. mesalazine. In this study, budesonide 9 mg/ day was a more effective induction therapy than mesalazine 4 g/day [65] . A meta-analysis showed that budesonide induces more frequently remission than placebo or 5-ASA with an OR of 1.85 in favour of budesonide vs. placebo [66] .
Mantzaris et al. [67] found that endoscopic remission was achieved in only 24% of patients administered budesonide compared with 83 % administered azathioprine (p \ 0.01), indicating that immunomodulators are more effective than budesonide in achieving mucosal healing.
Thus, budesonide is safe and effective as an induction therapy for mild to moderate CD involving the terminal ileum and the proximal colon.
Maintenance of Remission
Budesonide is superior to placebo for CD remission and it is well tolerated even if it is taken for up to 1 year [68] . However, budesonide is not prolonging the time to relapse in CD patients. This has been investigated in several studies, summarised in Table 3 .
Budesonide is not the drug of choice for the maintenance of remission. This observation is based on a pooled analysis of five trials [69] [70] [71] [72] [73] . All trials evaluated patients with quiescent luminal disease at 52 weeks. Those five trials have been summarized in a systematic review and meta-analysis [56] . No statistically significant difference could be detected between budesonide and placebo in terms of prevention of relapse (risk ratio 0.93; 95 % CI 0.83-1.04). Similar results were published in a Cochrane study [34] and in a meta-analysis [74] .
In summary, budesonide is not significantly more effective than placebo [34, 54, [70] [71] [72] [73] [75] [76] [77] or systemic corticosteroids [78] in maintaining clinical remission in CD.
Other Agents
Two additional substances should be mentioned only briefly as those were not the scope of this review. One is a novel formulation of budesonide that has recently been developed. It uses the multimatrix delivery system (MMX Ò ), a special drug-release system characterised by a pH-dependent hydrophilic and inert matrix that acts as a gastroprotective layer, allowing release of the drug only when pH rises above 7. Therefore, it targets the entire colon and could be used in colonic CD [79] [80] [81] . The second agent is beclomathasone dipropionate. It is a topicalacting corticosteroid that is administered as a pro-drug with a rapid first-pass effect [82] . Only limited data are available. One study showed superiority of budesonide over beclomathasone dipropionate with remission rates at 8 weeks of 86.6 vs. 66.6 % (p \ 0.001) [62] . 6-Mercaptopurine and its pro-drug azathioprine are purine analogues that competitively interfere with nucleic acid metabolism by acting as substrate competitive antagonists for the hypoxanthine-guanine phosphoribosyl-transferase enzyme [83] . Consequently, both drugs have immune modifier properties by reducing the cell proliferation. Both drugs have been used successfully to treat patients with active, corticosteroid-refractory, and corticosteroid-dependent inflammatory CD, and patients with fistulising CD [84] . In some azathioprine and 6-mercaptopurine studies, the corticosteroid-sparing effect of therapy was a primary outcome [85] [86] [87] [88] [89] . It was assessed variously as (1) the ability to follow a pre-defined corticosteroid-tapering regimen, and (2) as the ability to reduce a corticosteroid dose to \10 mg/day while maintaining remission. In the five studies reporting data on the reduction of corticosteroid use, patients with active disease who received antimetabolites reduced their corticosteroid use more significantly compared with placebo [85] [86] [87] [88] 90] . In a meta-analysis, the pooled OR was 3.69 (95 % CI 2.12-6.42), indicating a significant corticosteroid-sparing effect [84] . The NNT to obtain a corticosteroid-sparing effect in one patient was 3.
Anti-TNF-antibodies
In ACCENT I, 25 % of the patients who received 5 mg/kg of infliximab and 34 % of patients who received 10 mg/kg of infliximab were able to completely discontinue corticosteroid therapy altogether and remain in remission [91] .
In the CHARM trial, 35 % of the randomized responders who received adalimumab 40 mg every other week were off corticosteroid therapy and in remission at week 26 compared with only 3 % of placebo patients (p \ 0.001). At week 56, 29 % of patients who received adalimumab 40 mg every other week were in remission and off corticosteroids compared with only 6 % of placebo-treated patients (p = 0.008) [92] . No comparable studies exist on certolizumab pegol. As mentioned above, over 50 % of patients become corticosteroid dependent or underwent surgery within 1 year of commencing therapy [14] . Immunosuppressives and anti-TNF-antibodies can reduce corticosteroid dependency and maintain disease remission and should therefore be considered early in the therapy.
Summary and Practical Tips
Based on the National Institute for Health and Clinical Excellence clinical guidelines, published in 2012, we will offer best practice advice on the care of patients with CD [93] . Because corticosteroids are rapidly active and highly effective, they remain the mainstay for the induction of clinical remission of CD. If a patient needs to start on corticosteroids, use 0.5-0.75 mg/kg (or 40 mg/day) daily [21, [42] [43] [44] . Offer, whenever possible, monotherapy with a glucocorticosteroid (prednisolone, methylprednisolone or intravenous hydrocortisone) to induce remission especially in people with a first presentation or a single inflammatory exacerbation of CD in a 12-month period [93] . In people with one or more of distal ileal, ileocaecal or right-sided colonic disease who decline, cannot tolerate or in whom a conventional glucocorticosteroid is contraindicated, consider budesonide for a first presentation or a single inflammatory exacerbation in a 12-month period. Explain to the patient, however, that budesonide is less effective than a conventional glucocorticosteroid, but may have fewer adverse effects [93] .
Obviously, there is an increased concern about adverse effects associated with long-term conventional corticosteroid use, including suppression of the adrenal axis. Thus, clinicians must always consider a quick tapering of the dose and adverse events when using an appropriate maintenance therapy. When a clinical response has been achieved, doses are tapered according to the rapidity and completeness of response. Generally, doses are tapered by 5-10 mg/week until 20 mg and then by 2.5-5 mg/week until discontinuation of therapy. In people who decline, cannot tolerate or in whom glucocorticosteroid treatment is contraindicated, consider 5-ASA treatment for a first presentation or a single inflammatory exacerbation in a 12-month period. Explain that 5-ASA is less effective than a conventional glucocorticosteroid or budesonide, but may have fewer adverse effects than a conventional glucocorticosteroid [93] . However, always remember, do not offer budesonide or 5-ASA treatment for severe presentations or exacerbations [93] .
In summary: within the changing landscape of available treatments in CD, glucocorticosteroids still remain an important therapy regardless of short-and long-term adverse effects.
